ACRS250117C8000
- 0.00
- 0.000.00%
Aclaris Therapeutics Newsroom
Aclaris Therapeutics Analyst Ratings
H.C. Wainwright Upgrades Aclaris Therapeutics(ACRS.US) to Buy Rating, Announces Target Price $20
Jefferies Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $7
Aclaris Therapeutics: Promising Pipeline and Strong Financial Outlook Drive Buy Rating
Stifel Maintains Aclaris Therapeutics(ACRS.US) With Hold Rating, Raises Target Price to $5
Stifel Nicolaus Remains a Hold on Aclaris Therapeutics (ACRS)
Cantor Fitzgerald Upgrades Aclaris Therapeutics(ACRS.US) to Buy Rating
Aclaris Therapeutics Price Target Raised to $7.00/Share From $2.00 by Leerink Partners
Aclaris Therapeutics Raised to Outperform From Market Perform by Leerink Partners
A Quick Look at Today's Ratings for Aclaris Therapeutics(ACRS.US), With a Forecast Between $3 to $13
Jefferies Upgrades Aclaris Therapeutics to Buy, Price Target Is $7
Promising Potential of Aclaris Therapeutics' BSI-045B and Pipeline Elevates Buy Rating
Piper Sandler: Authorized trade is transformative. Target price for Aclaris (ACRS.US) is significantly raised to $13.
Aclaris Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Aclaris Therapeutics (ACRS), McKesson (MCK) and Enhabit, Inc (EHAB)
Aclaris Therapeutics: Hold Rating Amid Mixed Trial Outcomes and Strategic Uncertainties
Stifel Maintains Aclaris Therapeutics(ACRS.US) With Hold Rating, Raises Target Price to $3
Stifel Nicolaus Sticks to Its Hold Rating for Aclaris Therapeutics (ACRS)
BTIG Maintains Aclaris Therapeutics(ACRS.US) With Hold Rating
H.C. Wainwright Maintains Aclaris Therapeutics(ACRS.US) With Hold Rating